Next generation automated traceless cell chromatography platform for GMP-compliant cell isolation and activation

Area of Science:

• Biotechnology
• Immunology
• Cell Therapy Manufacturing

Background:

• Current methods for isolating target cells in immuno-oncology rely on magnetic nanoparticles, which can remain on cells.
• This poses challenges for downstream manufacturing and therapeutic applications.

Purpose of the Study:

• To develop a novel, clinical-grade cell isolation platform for personalized cell therapy.
• To introduce a system that overcomes limitations of existing cell isolation technologies.

Main Methods:

• Development of Automated Traceless Cell affinity chromatography (ATC), a closed, GMP-compliant system.
• Utilizing reversible immunoaffinity reagents for non-magnetic column chromatography.
• Integration with Streptamer-based technologies for sequential selection and on-column activation.

Main Results:

• ATC enables efficient and traceless isolation of specific cell subsets.
• The system supports sequential positive cell selection and depletion strategies.
• On-column cell activation is achievable, enhancing versatility.

Conclusions:

• ATC is an innovative and versatile platform for clinical-grade cell manufacturing.
• The technology facilitates precise cell selection, stimulation, and modification for downstream therapies.
• ATC advances personalized cell therapy by providing a closed, automated, and compliant manufacturing solution.